Evidence map›Paper›PMID 39687241›Full record

ArticleRevista panamericana de salud publica = Pan American journal of public health2024

[COVID-19 vaccine safety: results of active surveillance at a sentinel site in ArgentinaSegurança das vacinas contra COVID-19: resultados da vigilância ativa em uma unidade sentinela da Argentina].

Nerina Ivana Lescura, Carolina Selent, Mariana Noel Guerci, Octavia María Bertachini, María Victoria López, Ana Martina de Prada, María Del Valle Fernández, Nancy Vivian Barboza, María Del Valle Juárez, Analía Florencia Cáceres and 4 more

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Revista panamericana de salud publica = Pan American journal of public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nerina Ivana LescuraDepartamento de Epidemiología Hospital Provincial Neuquén Dr. Castro Rendón Neuquén Argentina Departamento de Epidemiología, Hospital Provincial Neuquén, Dr. Castro Rendón, Neuquén, Argentina.
Carolina SelentDirección de Control de Enfermedades Inmunoprevenibles Ministerio de Salud de la Nación Ciudad Autónoma de Buenos Aires Argentina Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Ciudad Autónoma de Buenos Aires, Argentina.
Mariana Noel GuerciDepartamento de Epidemiología Hospital Provincial Neuquén Dr. Castro Rendón Neuquén Argentina Departamento de Epidemiología, Hospital Provincial Neuquén, Dr. Castro Rendón, Neuquén, Argentina.
Octavia María BertachiniDirección de Control de Enfermedades Inmunoprevenibles Ministerio de Salud de la Nación Ciudad Autónoma de Buenos Aires Argentina Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Ciudad Autónoma de Buenos Aires, Argentina.
María Victoria LópezDirección de Control de Enfermedades Inmunoprevenibles Ministerio de Salud de la Nación Ciudad Autónoma de Buenos Aires Argentina Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Ciudad Autónoma de Buenos Aires, Argentina.
Ana Martina de PradaDirección de Control de Enfermedades Inmunoprevenibles Ministerio de Salud de la Nación Ciudad Autónoma de Buenos Aires Argentina Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Ciudad Autónoma de Buenos Aires, Argentina.
María Del Valle FernándezDepartamento de Epidemiología Hospital Provincial Neuquén Dr. Castro Rendón Neuquén Argentina Departamento de Epidemiología, Hospital Provincial Neuquén, Dr. Castro Rendón, Neuquén, Argentina.
Nancy Vivian BarbozaDepartamento de Epidemiología Hospital Provincial Neuquén Dr. Castro Rendón Neuquén Argentina Departamento de Epidemiología, Hospital Provincial Neuquén, Dr. Castro Rendón, Neuquén, Argentina.
María Del Valle JuárezDirección de Control de Enfermedades Inmunoprevenibles Ministerio de Salud de la Nación Ciudad Autónoma de Buenos Aires Argentina Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Ciudad Autónoma de Buenos Aires, Argentina.
Analía Florencia CáceresOrganización Panamericana de la Salud Washington D.C. Estados Unidos de América Organización Panamericana de la Salud, Washington D.C., Estados Unidos de América.
Carlos FallaOrganización Panamericana de la Salud Washington D.C. Estados Unidos de América Organización Panamericana de la Salud, Washington D.C., Estados Unidos de América.
Ivonne Natalia SolarteOrganización Panamericana de la Salud Washington D.C. Estados Unidos de América Organización Panamericana de la Salud, Washington D.C., Estados Unidos de América.
Florencia BruggesserDirección de Control de Enfermedades Inmunoprevenibles Ministerio de Salud de la Nación Ciudad Autónoma de Buenos Aires Argentina Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Ciudad Autónoma de Buenos Aires, Argentina.
Daniel StecherDirección de Control de Enfermedades Inmunoprevenibles Ministerio de Salud de la Nación Ciudad Autónoma de Buenos Aires Argentina Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Ciudad Autónoma de Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To analyze the results of surveillance of adverse events of special interest (AESI) within the context of the COVID-19 vaccination campaign at a sentinel site in Argentina. The retrospective (pre-vaccination) period was compared with the prospective (vaccination) period to identify safety signals. Methods: Retrospective and prospective search for AESI based on ICD-10 hospital discharge codes. A descriptive analysis, moving-averages trend smoothing, and control charts were used to detect changes in AESI behavior. Results: A total of 1,586 AESI were identified. Analysis of the proportion of AESI codes at hospital discharge revealed an increase during the pandemic period (2020) and a progressive decrease during the vaccination period (2021-2022), accounted for by the incidence of acute respiratory distress syndrome (ARDS). Moving-average smoothing and control charts were compared to identify time points at which the proportion of AESI exceeded the upper limits of control. During the vaccination period, this occurred for ARDS, thrombosis, myocarditis, meningoencephalitis, multisystem inflammatory syndrome, and anaphylaxis. No differences were observed for Guillain-Barré syndrome, thrombocytopenia, or pericarditis. Acute disseminated encephalomyelitis, meningoencephalitis, and pericarditis events during the vaccination period all occurred in subjects with no history of vaccination. Conclusion: Active sentinel-site surveillance allowed identification of AESI occurring at a higher frequency during the vaccination period compared to the pre-vaccination baseline. The protective effect of the vaccine against COVID -19 was clearly observed, as manifested especially by a reduction of ARDS cases in the post-vaccination period. This strategy is useful for assessing vaccine safety by identification of safety signals.

Indexed as

adverse eventArgentinaCOVID-19 vaccineshealth surveillance systempharmacovigilanceSARS-CoV-2Vaccines

Identifiers

PMID39687241
PMCPMC11648208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.